Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.
Angelyn AntonSruti PillaiMarie Christine SemiraShirley WongJulia ShapiroAndrew WeickhardtArun A AzadEdmond M KwanLavinia SpainAshray GunjurJavier TorresPhillip ParenteFrancis ParnisJeffrey GohOlivia BaenzigerPeter GibbsBen TranPublished in: BJUI compass (2021)
In our real-world population, ENZ and AA were common first-line systemic therapy choices, particularly among older patients and those with poorer performance status. Patients receiving ENZ and AA demonstrated superior TTF compared to DOC, while OS was not statistically different. Our findings highlight the important role of ARSIs, given the variability of access worldwide.